TUSTIN, Calif., July 14 /PRNewswire-FirstCall/ -- (http://www.amdl.com) AMDL, Inc., (Amex: ADL) a leading vertically integrated bio-pharmaceutical company with major operations in China and the US, announced that the AMDL-ELISA DR- 70(R) (FDP) test has been shown to be a useful test for the detection of cancer in clinical practice according to an independent study of 185 patients from the Medical Department II at the University Hospital in Frankfurt Germany. The results were published in the international medical research publication Alimentary Pharmacology & Therapeutics.
The purpose of this independent study was to evaluate the potential of the DR-70 ELISA (FDP) test as a detection test for gastrointestinal cancers that include, colorectal, esophageal, gallbladder, gastric, liver, pancreatic and intestinal cancers. Additionally, the quantitative value of DR-70 (FDP) was tested as a parameter for the progression of these cancers. Serum samples were taken from a total of 80 cancer patients with histologically proven malignant tumors and 100 healthy blood donors in this study. Patients with colorectal cancer were also tested for carcinoembryogenic antigen (CEA), a competing diagnostic test to AMDL-ELISA DR-70 (FDP). The complete article about AMDL-ELISA DR-70 (FDP) can be accessed via AMDL's corporate website located at http://www.amdl.com under the RESOURCES link.
"When we compared the DR-70 immunoassay with conventional tumor
markers, DR-70 turned out to be superior to CEA in the detection of
patients with colorectal cancer," according to the conclusion of authors.
The authors also concluded that DR-70 (FDP) levels were shown to be
significantly higher across all types of gastrointestinal cancers tested
and not limited to specific tumor types, suggesting the AMDL-ELISA DR-70
(FDP) test could be clinically used as a global cancer detection tool.
According to the results:
-- The AMDL-ELISA DR-70 (FDP) test showed strong clinical performance
with a sensitivity of 91% and a specificity of 93% in testing
conducted on patients with hepatocellular, cholangiocellular,
pancreatic, colorectal, stomach and oesophagus cancers.
-- The test reliably differs between patients with cancer of the
gastrointestinal tract or the hepatobilary system and healthy
patients; therefore showing promise as a useful cancer detection tool
in clinical practice.
-- The study also found an association between the quantitative DR-70
value and the stage of the cancer in patients tested which suggests
the AMDL-ELISA DR-70 (FDP) test can also be used as a prognostic
factor in cancer monitoring.
About AMDL: Headquartered in Tustin, CA with operations in Shenzhen,
Jiangxi, and Jilin, China, AMDL, Inc., along with its subsidiary Jade
Pharmaceutical Inc. (JPI), is a vertically integrated bio-pharmaceutical
company devoted to the research, development, manufacturing, and marketing
of diagnostic, pharmaceutical, nutritional supplement, and cosmetic
products. The company employs approximately 320 people in the U.S. and
China. The AMDL ELISA DR-70 (FDP) cancer diagnostic test was cleared to
market by the US FDA on July 13, 2008 and the Company has 4 additional
pharmaceutical and diagnostic products under review by various regulatory
authorities. For additional information on AMDL and its products visit the
company's website at http://www.amdl.com or call +1 (714)505-4460.
(M) (206) 310-5323
(O) (206) 201-3286
|SOURCE AMDL, Inc.|
Copyright©2008 PR Newswire.
All rights reserved